4 March 2020

Thermo Fisher Scientific to acquire QIAGEN

+ 6 other team members
Thermo Fisher Scientific, the world leader in serving science, and QIAGEN, a Germany-based pharmaceutical company, have agreed to combine their businesses and create a leading global biotechnology company.

This was the first German/US public offer ever made for a Dutch NV company. As lead counsel to QIAGEN, we led an international team of lawyers advising QIAGEN on this multi-billion cross-border transaction.

Read more about this deal here.

De Brauw team: Arne Grimme, Martin van Olffen, Bernard Spoor, Casper Nagtegaal, Frank Hamming, Eveline de Waard, Ioana Patrascu, Matthijs Verwer, Maarten van der Weijden, Klaas Versteeg and Pim Siemons.